International Journal of Molecular Sciences · 2018 · 25 citations · 33 references
Life SciencesBiochemistryMolecular BiologyGene ExpressionMetabolismProteomicsCholesterol MetabolismFatty Acid MetabolismLipid MetabolismLipid SignalingPeroxisomal BiochemistryPeroxisomal MetabolismLipid Metabolism Gene ExpressionLipid Metabolism PathwaysPeroxisome Proliferator-activated Receptor Alpha (Ppar-alpha) SignalingPeroxisome SignalingSterol Regulatory Element-binding Protein RegulationSterol Regulatory Element-binding ProteinsTissue Expression ProfilesTransgenic Mouse Models
The key lipid metabolism transcription factor sterol regulatory element-binding protein (SREBP)-1a integrates gene regulatory effects of hormones, cytokines, nutrition and metabolites as lipids, glucose, or cholesterol via phosphorylation by different mitogen activated protein kinase (MAPK) cascades. We have previously reported the impact of SREBP-1a phosphorylation on the phenotype in transgenic mouse models with liver-specific overexpression of the N-terminal transcriptional active domain of SREBP-1a (alb-SREBP-1a) or a MAPK phosphorylation site-deficient variant (alb-SREBP-1a∆P; (S63A, S117A, T426V)), respectively. In this report, we investigated the molecular basis of the systemic observations by holistic analyses of gene expression in liver and of proteome patterns in lipid-degrading organelles involved in the pathogenesis of metabolic syndrome, i.e., peroxisomes, using 2D-DIGE and mass spectrometry. The differences in hepatic gene expression and peroxisomal protein patterns were surprisingly small between the control and alb-SREBP-1a mice, although the latter develop a severe phenotype with visceral obesity and fatty liver. In contrast, phosphorylation site-deficient alb-SREBP-1a∆P mice, which are protected from fatty liver disease, showed marked differences in hepatic gene expression and peroxisomal proteome patterns. Further knowledge-based analyses revealed that disruption of SREBP-1a phosphorylation resulted in massive alteration of cellular processes, including signs for loss of targeting lipid pathways.
33
Nonalcoholic Fatty Liver, Steatohepatitis, and the Metabolic Syndrome
Giulio Marchesini, Elisabetta Bugianesi, Gabriele Forlani et al. · Hepatology · 2003 · 2.7K citations · Full text
Iichiro Shimomura, Hitoshi Shimano, Jay D. Horton et al. · Journal of Clinical Investigation · 1997 · 754 citations · Full text